Revolutionizing Chimerism Monitoring

The latest innovation in chimerism testing offers streamlined workflow with best-in-class sensitivity.

Chimerism changes after hematopoietic cell transplant can be an early indication of relapse.*

Key Features

• A NGS based chimerism testing solution that is able to determine the relative contribution of up to 3 genomes in a single sample i.e. up to two donors per recipient 

• A kit based test that offers high quality data with a recommended input of 10 ng of gDNA and up to 96 samples per batch 

• One-step multiplex assay that utilizes 202 SNPs across all autosomal chromosomes to differentiate between recipient and donor(s) gDNA 

• A highly sensitive, scalable assay with time-saving automated analysis software

*AlloSeq HCT and AlloSeq HCT Software are available either as CE/IVD or Research Use Only (RUO), depending local regulatory status. For more details on local regulatory status, please contact GenDx. RUO products are not to be used for diagnostic procedures. AlloSeq is a trademark or registered trademark of CareDx Inc. or its subsidiaries in the US or other countries and used under license. AlloSeq is a registered trademark with the US Patent and Trademark Office.